Psy56 - Cost-Utility of New Film-Coated Tablet Formulation of Deferasirox Versus Deferoxamine Among Major B-Thalassemia Patients in Iran

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2632
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Renal Function in Β-Thalassemia Major Receiving Desferal Versus Deferasirox

Journal of Renal Injury Prevention
UrologyNephrology
2017English

Patient-Reported Outcomes From a Randomized Phase II Study of the Deferasirox Film-Coated Tablet in Patients With Transfusion-Dependent Anemias

Health and Quality of Life Outcomes
MedicineEnvironmentalPublic HealthOccupational Health
2018English

Different Types of Complications in Patients Suffering From B-Thalassemia (Thalassemia Major)

Journal of Gandhara Medical and Dental Science
2017English

Regression of Cardiac Insufficiency After Ambulatory Intravenous Deferoxamine in Thalassemia Major

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
1993English

Comparison of Cardiac Dysfunction in Thalassemia Major Patients Using Deferoxamine or Deferiprone as an Iron-Chelating Agent

Paediatrica Indonesiana
2012English

Deferasirox (Exjade®) Significantly Improves Cardiac T2* in Heavily Iron-Overloaded Patients With Β-Thalassemia Major

Annals of Hematology
MedicineHematology
2009English

MRI Multicentre Prospective Survey in Thalassaemia Major Patients Treated With Deferasirox Versus Deferiprone and Desferrioxamine

British Journal of Haematology
Hematology
2018English

Hepatitis B Virus Infection in Thalassemia Major.

BMJ
1984English

Influence of Patient-Reported Outcomes on the Treatment Effect of Deferasirox Film-Coated and Dispersible Tablet Formulations in the ECLIPSE Trial: A Post-Hoc Mediation Analysis

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy